Late-breakers to look out for at ASCO 2026
ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
Oral Wegovy backed by CHMP at May meeting
The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.
GBL joins CVC in €10.7bn takeover bid for Recordati
A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
NICE changes stance on Genmab's cervical cancer drug
After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.
Biogen, Denali pull Parkinson's drug after failed trial
Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions